Frissora, Christine L.
Schiller, Lawrence R.
Article History
Accepted: 7 December 2023
First Online: 30 December 2023
Declarations
:
: Disclosures: Dr. Frissora reports non-financial support from QOL Speaker bureau, personal fees from Advisory boards: Ardelyx, Ironwood, Salix, personal fees from Legal consulting work, other from GI Reconnect, other from Vibrant Capsule Advisory Board, Israel, non-financial support from TRAC Tri-Institutional Research Advancement Center Committee Weill Cornell Medical Center, outside the submitted work. Dr. Schiller reports personal fees from Salix Pharmaceuticals, outside the submitted work.
: Ethics approval was not required for this review.
: Dr. Frissora reports non-financial support from QOL Speaker bureau, personal fees from Advisory boards: Ardelyx, Ironwood, Salix, personal fees from Legal consulting work, other from GI Reconnect, other from Vibrant Capsule Advisory Board, Israel, non-financial support from TRAC Tri-Institutional Research Advancement Center Committee Weill Cornell Medical Center, outside the submitted work. Dr. Schiller reports personal fees from Salix Pharmaceuticals, outside the submitted work.
: The authors declare no competing interests.
: This article does not contain any studies with human or animal subjects performed by any of the authors.